Elanco Animal Health (ELAN) Stock Forecast, Price Target & Predictions
ELAN Stock Forecast
Elanco Animal Health stock forecast is as follows: an average price target of $17.50 (represents a 42.16% upside from ELAN’s last price of $12.31) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
ELAN Price Target
The average price target for Elanco Animal Health (ELAN) is $17.50 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $14.00. This represents a potential 42.16% upside from ELAN's last price of $12.31.
ELAN Analyst Ratings
According to 7 Wall Street analysts, Elanco Animal Health's rating consensus is 'Buy'. The analyst rating breakdown for ELAN stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 2 'Hold' (28.57%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Elanco Animal Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 09, 2024 | Andrea Alfonso | UBS | $18.00 | $12.50 | 44.00% | 46.22% |
| Dec 02, 2024 | Daniel Clark | Leerink Partners | $14.00 | $13.16 | 6.38% | 13.73% |
| Sep 23, 2024 | Balaji Prasad | Barclays | $22.00 | $14.07 | 56.36% | 78.72% |
| Jul 01, 2024 | David Westenberg | Piper Sandler | $16.00 | $14.43 | 10.88% | 29.98% |
| May 13, 2024 | David Westenberg | Piper Sandler | $19.00 | $17.00 | 11.76% | 54.35% |
| Mar 12, 2024 | David Westenberg | Piper Sandler | $18.00 | $15.77 | 14.14% | 46.22% |
| Jan 05, 2024 | Jonathan Block | Stifel Nicolaus | $20.00 | $15.45 | 29.45% | 62.47% |
| Sep 12, 2022 | Barclays | $18.00 | $15.00 | 20.00% | 46.22% | |
| Aug 16, 2022 | David Westenberg | Piper Sandler | $21.00 | $19.08 | 10.06% | 70.59% |
| Jul 18, 2022 | J.P. Morgan | $32.00 | $20.14 | 58.89% | 159.95% | |
| Jun 24, 2022 | Stifel Nicolaus | $22.00 | $19.94 | 10.33% | 78.72% | |
| May 19, 2022 | Goldman Sachs | $32.00 | $23.35 | 37.04% | 159.95% | |
| May 17, 2022 | Morgan Stanley | $37.00 | $23.73 | 55.92% | 200.57% |
The latest Elanco Animal Health stock forecast, released on Dec 09, 2024 by Andrea Alfonso from UBS, set a price target of $18.00, which represents a 44.00% increase from the stock price at the time of the forecast ($12.50), and a 46.22% increase from ELAN last price ($12.31).
Elanco Animal Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 3 | 7 |
| Avg Price Target | $16.00 | $18.00 | $18.14 |
| Last Closing Price | $12.31 | $12.31 | $12.31 |
| Upside/Downside | 29.98% | 46.22% | 47.36% |
In the current month, the average price target of Elanco Animal Health stock is $16.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 29.98% increase as opposed to Elanco Animal Health's last price of $12.31. This month's average price target is down -11.11% compared to last quarter, and down -11.80% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 09, 2024 | UBS | Buy | Initialise | |
| Dec 02, 2024 | Leerink Partners | Market Perform | Initialise | |
| Oct 28, 2024 | Morgan Stanley | Buy | Buy | Hold |
| Sep 23, 2024 | Barclays | Overweight | Overweight | Hold |
| Sep 20, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Sep 19, 2024 | Morgan Stanley | Underperform | Underperform | Hold |
| Sep 19, 2024 | Piper Sandler | Buy | Buy | Hold |
| Sep 19, 2024 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| Jul 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 13, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| May 09, 2024 | Bank of America Securities | Buy | Buy | Hold |
| May 09, 2024 | Barclays | Overweight | Overweight | Hold |
| Jan 17, 2024 | Goldman Sachs | Sell | Sell | Hold |
| Apr 20, 2023 | Barclays | Equal-Weight | Overweight | Upgrade |
| Sep 12, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Aug 18, 2022 | Morgan Stanley | Overweight | Overweight | Downgrade |
| Aug 16, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| May 19, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 17, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 28, 2022 | Barclays | Equal-Weight | Equal-Weight | Hold |
Elanco Animal Health's last stock rating was published by UBS on Dec 09, 2024. The company Initialise its ELAN rating from "null" to "Buy".
Elanco Animal Health Financial Forecast
Elanco Animal Health Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.07B | $1.06B | $1.26B | $988.00M | $1.03B | $1.18B | $1.23B | $1.11B | $1.13B | $1.28B | $1.24B | $1.14B | $889.60M | $586.30M | $657.70M | $787.00M | $771.30M |
| Avg Forecast | $1.10B | $1.13B | $1.22B | $1.28B | $1.07B | $1.08B | $1.18B | $1.22B | $1.01B | $1.04B | $1.15B | $1.19B | $1.00B | $1.04B | $1.04B | $1.19B | $980.94M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| High Forecast | $1.11B | $1.14B | $1.23B | $1.29B | $1.07B | $1.09B | $1.19B | $1.23B | $1.02B | $1.05B | $1.15B | $1.19B | $1.01B | $1.04B | $1.05B | $1.20B | $988.45M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| Low Forecast | $1.10B | $1.12B | $1.21B | $1.27B | $1.06B | $1.07B | $1.17B | $1.20B | $1.00B | $1.03B | $1.15B | $1.18B | $988.87M | $1.04B | $1.03B | $1.18B | $973.31M | $1.03B | $1.18B | $1.22B | $1.10B | $1.08B | $1.24B | $1.16B | $1.05B | $913.80M | $575.44M | $721.62M | $790.45M | $764.69M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.05% | 1.01% | 1.00% | 1.00% | 1.01% | 1.01% | 1.05% | 1.03% | 1.07% | 1.08% | 0.97% | 1.02% | 0.91% | 1.00% | 1.01% |
Elanco Animal Health's average Quarter revenue forecast for Dec 23 based on 7 analysts is $1.00B, with a low forecast of $988.87M, and a high forecast of $1.01B. ELAN's average Quarter revenue forecast represents a -6.21% decrease compared to the company's last Quarter revenue of $1.07B (Sep 23).
Elanco Animal Health EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $42.00M | $166.00M | $346.00M | $136.00M | $211.00M | $268.00M | $345.00M | $108.00M | $100.00M | $-6.00M | $183.00M | $-35.50M | $-28.60M | $28.60M | $30.20M | $97.80M | $84.90M |
| Avg Forecast | $79.77M | $81.42M | $88.42M | $92.17M | $76.97M | $78.13M | $85.20M | $87.78M | $73.12M | $74.87M | $82.94M | $351.45M | $72.37M | $75.11M | $74.97M | $319.50M | $90.85M | $188.14M | $214.61M | $290.46M | $201.16M | $197.23M | $226.36M | $78.77M | $192.24M | $166.54M | $104.88M | $39.64M | $144.06M | $139.37M |
| High Forecast | $80.38M | $82.05M | $89.10M | $92.87M | $77.55M | $78.72M | $85.85M | $88.51M | $73.84M | $75.58M | $82.94M | $421.74M | $73.11M | $75.18M | $75.54M | $383.40M | $109.02M | $188.14M | $214.61M | $348.55M | $201.16M | $197.23M | $226.36M | $94.52M | $192.24M | $166.54M | $104.88M | $47.56M | $144.06M | $139.37M |
| Low Forecast | $79.15M | $80.79M | $87.74M | $91.45M | $76.37M | $77.52M | $84.54M | $87.06M | $72.55M | $74.16M | $82.94M | $281.16M | $71.44M | $75.03M | $74.38M | $255.60M | $72.68M | $188.14M | $214.61M | $232.37M | $201.16M | $197.23M | $226.36M | $63.02M | $192.24M | $166.54M | $104.88M | $31.71M | $144.06M | $139.37M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.56% | 2.21% | 1.08% | 1.50% | 1.12% | 1.25% | 1.19% | 0.54% | 0.51% | -0.03% | 2.32% | -0.18% | -0.17% | 0.27% | 0.76% | 0.68% | 0.61% |
7 analysts predict ELAN's average Quarter EBITDA for Dec 23 to be $72.37M, with a high of $73.11M and a low of $71.44M. This is 72.30% upper than Elanco Animal Health's previous annual EBITDA (Sep 23) of $42.00M.
Elanco Animal Health Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.10B | $-97.00M | $103.00M | $-54.00M | $-49.00M | $-22.00M | $48.00M | $-97.00M | $-104.00M | $-210.00M | $-61.00M | $-322.80M | $-135.00M | $-53.20M | $-49.10M | $-9.50M | $10.00M |
| Avg Forecast | $96.55M | $78.95M | $151.98M | $175.89M | $88.85M | $72.72M | $138.17M | $153.07M | $75.88M | $60.92M | $119.29M | $56.42M | $52.03M | $62.03M | $23.43M | $51.29M | $-81.59M | $78.39M | $124.66M | $46.63M | $83.20M | $81.70M | $132.68M | $-26.26M | $48.79M | $59.80M | $18.46M | $-64.44M | $112.45M | $126.68M |
| High Forecast | $97.51M | $79.74M | $153.50M | $177.63M | $89.74M | $73.45M | $139.54M | $162.64M | $80.94M | $61.53M | $119.37M | $67.70M | $67.64M | $63.43M | $23.66M | $61.55M | $-65.28M | $78.39M | $124.66M | $55.95M | $83.20M | $81.70M | $132.68M | $-21.01M | $48.79M | $59.80M | $18.46M | $-51.55M | $112.45M | $126.68M |
| Low Forecast | $95.58M | $78.15M | $150.44M | $174.11M | $87.95M | $71.99M | $136.77M | $143.51M | $70.83M | $60.31M | $119.21M | $45.14M | $41.62M | $60.63M | $23.19M | $41.03M | $-97.91M | $78.39M | $124.66M | $37.30M | $83.20M | $81.70M | $132.68M | $-31.51M | $48.79M | $59.80M | $18.46M | $-77.33M | $112.45M | $126.68M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.67% | -4.14% | 2.01% | 0.66% | -0.63% | -0.18% | 1.03% | -1.17% | -1.27% | -1.58% | 2.32% | -6.62% | -2.26% | -2.88% | 0.76% | -0.08% | 0.08% |
Elanco Animal Health's average Quarter net income forecast for Jun 23 is $23.43M, with a range of $23.19M to $23.66M. ELAN's average Quarter net income forecast represents a -77.26% decrease compared to the company's last Quarter net income of $103.00M (Mar 23).
Elanco Animal Health SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $313.00M | $353.00M | $327.00M | $303.00M | $298.00M | $343.00M | $320.00M | $329.00M | $342.00M | $385.00M | $348.00M | $374.10M | $277.70M | $162.80M | $364.00M | $237.30M | $243.00M |
| Avg Forecast | $314.49M | $321.00M | $348.60M | $363.36M | $303.43M | $308.00M | $335.89M | $346.06M | $288.25M | $295.16M | $326.97M | $376.14M | $285.29M | $296.10M | $295.55M | $341.94M | $276.75M | $294.02M | $335.38M | $310.86M | $314.37M | $308.22M | $353.76M | $149.79M | $300.43M | $260.27M | $163.90M | $477.75M | $225.14M | $217.80M |
| High Forecast | $316.90M | $323.45M | $351.26M | $366.14M | $305.75M | $310.36M | $338.46M | $348.92M | $291.10M | $297.96M | $326.97M | $451.36M | $288.22M | $296.39M | $297.81M | $410.33M | $332.10M | $294.02M | $335.38M | $373.03M | $314.37M | $308.22M | $353.76M | $179.75M | $300.43M | $260.27M | $163.90M | $573.30M | $225.14M | $217.80M |
| Low Forecast | $312.04M | $318.50M | $345.88M | $360.54M | $301.06M | $305.60M | $333.28M | $343.20M | $286.00M | $292.37M | $326.97M | $300.91M | $281.66M | $295.81M | $293.25M | $273.55M | $221.40M | $294.02M | $335.38M | $248.69M | $314.37M | $308.22M | $353.76M | $119.83M | $300.43M | $260.27M | $163.90M | $382.20M | $225.14M | $217.80M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.19% | 0.96% | 1.09% | 1.01% | 1.02% | 1.03% | 1.05% | 1.11% | 1.09% | 2.32% | 1.25% | 1.07% | 0.99% | 0.76% | 1.05% | 1.12% |
Elanco Animal Health's average Quarter SG&A projection for Dec 23 is $285.29M, based on 7 Wall Street analysts, with a range of $281.66M to $288.22M. The forecast indicates a -8.85% fall compared to ELAN last annual SG&A of $313.00M (Sep 23).
Elanco Animal Health EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 7 | 3 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 9 | 9 | 9 | 9 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.22 | $-0.20 | $0.21 | $-0.11 | $-0.10 | $-0.04 | $0.10 | $-0.20 | $-0.21 | $-0.43 | $-0.12 | $-0.66 | $-0.29 | $-0.13 | $-0.12 | $-0.03 | $0.03 |
| Avg Forecast | $0.19 | $0.16 | $0.31 | $0.35 | $0.18 | $0.15 | $0.28 | $0.31 | $0.15 | $0.12 | $0.24 | $0.27 | $0.10 | $0.12 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| High Forecast | $0.20 | $0.16 | $0.31 | $0.36 | $0.18 | $0.15 | $0.28 | $0.33 | $0.16 | $0.12 | $0.24 | $0.28 | $0.14 | $0.13 | $0.05 | $0.29 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| Low Forecast | $0.19 | $0.16 | $0.30 | $0.35 | $0.18 | $0.14 | $0.27 | $0.29 | $0.14 | $0.12 | $0.24 | $0.27 | $0.08 | $0.12 | $0.05 | $0.28 | $0.13 | $0.16 | $0.25 | $0.35 | $0.17 | $0.17 | $0.27 | $0.23 | $0.10 | $0.12 | $0.04 | $0.24 | $0.23 | $0.26 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -17.81% | -4.25% | 0.74% | -0.86% | -0.63% | -0.18% | 0.28% | -1.19% | -1.27% | -1.60% | -0.53% | -6.68% | -2.40% | -3.48% | -0.51% | -0.13% | 0.12% |
According to 6 Wall Street analysts, Elanco Animal Health's projected average Quarter EPS for Jun 23 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -77.59% decrease compared to ELAN previous annual EPS of $0.21 (Mar 23).
Elanco Animal Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ESPR | Esperion Therapeutics | $2.46 | $8.00 | 225.20% | Buy |
| IRWD | Ironwood Pharmaceuticals | $3.53 | $8.50 | 140.79% | Buy |
| LNTH | Lantheus | $92.66 | $155.00 | 67.28% | Buy |
| ELAN | Elanco Animal Health | $12.31 | $17.50 | 42.16% | Buy |
| COLL | Collegium Pharmaceutical | $30.90 | $42.33 | 36.99% | Buy |
| ALKS | Alkermes | $30.75 | $37.50 | 21.95% | Hold |
| PCRX | Pacira BioSciences | $19.83 | $23.75 | 19.77% | Hold |
| VTRS | Viatris | $12.59 | $15.00 | 19.14% | Hold |
| PBH | Prestige Consumer Healthcare | $80.39 | $89.50 | 11.33% | Buy |
| TEVA | Teva Pharmaceutical Industries | $20.88 | $23.20 | 11.11% | Buy |
| ITCI | Intra-Cellular Therapies | $86.96 | $93.33 | 7.33% | Buy |
| CTLT | Catalent | $63.48 | $63.50 | 0.03% | Hold |
| HLN | Haleon | $9.91 | $9.15 | -7.67% | Buy |
| PAHC | Phibro Animal Health | $22.34 | $18.67 | -16.43% | Buy |